Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Embryonic pig cell transplants halt rat diabetes

26.02.2004


Procedure requires no immune suppression drugs



An experimental cross-species transplant to treat diabetes has passed an early test in rats with better-than-expected results, suggesting the innovative approach might halt type 1 diabetes while greatly reducing the risk of rejection.

Scientists at Washington University School of Medicine in St. Louis set up control and experimental groups of rats with diabetes. The experimental group received embryonic pig pancreas cell transplants and antirejection drugs to prevent the rats’ immune systems from destroying the transplants. The control group received only the transplants and no immune suppression drugs. To the researchers’ surprise, the control group’s transplants grew unmolested by the immune system, halting the rats’ diabetes and changing the focus of the study to transplanting without the need for immune suppression.


"Every once in a while you get lucky, and now we have the possibility of transplanting these pig cells and not having to worry about rejection," says Marc R. Hammerman, M.D., the Chromalloy Professor of Renal Diseases in medicine and leader of the study.

The results appear online and will be published in the April issue of The American Journal of Physiology-Endocrinology and Metabolism.

Hammerman, an endocrinologist and director of the Renal Division, is a leader in the emerging field of organogenesis, which is focused on growing organs from stem cells and other embryonic cell clusters known as organ primordia. Unlike stem cells, primordia cannot develop into any cell type -- they are locked into becoming a particular cell type or one of a particular set of cell types that make up an organ.

In multiple groups of diabetic rats that were unable to produce their own rat insulin, Hammerman and Sharon Rogers, research instructor in medicine, transplanted pig pancreas primordia into the omentum, a membrane that envelops the intestines and other digestive organs. Within two weeks, the primordia engrafted and began producing pig insulin.

The pig insulin replaced the missing rat insulin, returning the rats’ blood glucose to normal levels, an effect that continued for the rest of their lives. Failure to gain weight, another characteristic symptom of diabetes, was also reversed following the transplants.

In a final group of transplant recipients, Rogers, Hammerman, Feng Chen, Ph.D., assistant professor of medicine, and Mike Talcott, D.V.M., director of veterinary surgical services, showed that pig insulin-producing cells were present in the omentum and had caused a buildup of fat, a change previously linked to successful engraftment of pancreatic tissue.

Hammerman had theorized for years that implanting primordia obtained very soon after organ formation and coaxing the cells into growing into fully functioning organs inside a transplant recipient might reduce immune system rejection. However, he admits he is stunned by the new success.

"Conditions that are permissive for transplantation from one species to another frequently don’t translate to transplants into another species," Hammerman says. "But this dramatic elimination of the need for immune suppression is quite unusual; there’s not a lot of precedent in the literature for it. So it’s possible that it may also apply in other cross-species transplants and maybe even in pig-to-human transplants."

Diabetes in humans is sometimes treated by transplanting human insulin-producing pancreas cells known as the islets of Langerhans. According to Hammerman, using embryonic pig cells as the transplant source instead of human islets circumvents three major difficulties.

"First, there aren’t nearly enough human pancreas organs to go around," Hammerman says. "Since pig insulin works fine in humans, if pigs could be used as donors the shortage would be alleviated."

Second, islets can only be extracted from the pancreas by mincing the organ and exposing it to enzymes that break down connective tissue.

"This damages islets," Hammerman says. "So not all of the transplanted islets engraft, and many that do engraft die after a period of time."

Third, islets are composed of mature cells unable to respond to increased need for their services by dividing and producing more cells. In contrast, embryonic pancreas cells divide readily in response to such needs, resulting in a potentially expandable source of insulin.

For reasons not yet understood, the transplanted pancreas cells did not develop an additional digestive function normally associated with the pancreas.

"That was another remarkably lucky break," Hammerman notes, "because only the endocrine cells are required to treat diabetes. The digestive cells would have only caused problems."

If elimination or reduction of immune rejection transfers to pig-to-human transplants, the technique will defeat or greatly diminish a final formidable obstacle to treating diabetes with transplants.

"Immunosuppressing a patient introduces a whole new set of dangers and side effects," says Hammerman. "Patients with type 1 diabetes have to ask themselves, would I rather take insulin, or would I rather take all these immunosuppressive drugs? It’s not the greatest choice in the world."

The next phase of research will involve pig-to-primate transplants. If those are successful, then pig-to-human transplant trials can be considered.

Hammerman also is studying the use of kidney primordia from embryonic pigs to grow new kidneys inside recipients as a treatment for end-stage kidney failure.


Rogers SA, Chen F, Talcott M, Hammerman MR. Islet cell engraftment and control of diabetes in rats after transplantation of pig pancreatic anlagen. American Journal of Physiology-Endocrinology and Metabolism, April 2004.

Funding from the National Institutes of Diabetes and Digestive and Kidney Diseases supported this research.

The full-time and volunteer faculty of Washington University School of Medicine are the physicians and surgeons of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Michael C. Purdy | EurekAlert!
Further information:
http://medinfo.wustl.edu/

More articles from Life Sciences:

nachricht New Test for Rare Immunodeficiency
23.08.2017 | Universität Basel

nachricht Repairing damaged hearts with self-healing heart cells
22.08.2017 | National University Health System

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Cholesterol-lowering drugs may fight infectious disease

22.08.2017 | Health and Medicine

Meter-sized single-crystal graphene growth becomes possible

22.08.2017 | Materials Sciences

Repairing damaged hearts with self-healing heart cells

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>